MedPath

Cefazolin

Generic Name
Cefazolin
Drug Type
Small Molecule
Chemical Formula
C14H14N8O4S3
CAS Number
25953-19-9
Unique Ingredient Identifier
IHS69L0Y4T
Background

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication

Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.

Associated Conditions
Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections
Associated Therapies
Antibiotic pre-surgical prophylaxis
Clinical Trials
Related News

Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support

Terminated
Conditions
Drug Effect
Interventions
First Posted Date
2019-04-22
Last Posted Date
2022-03-21
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
4
Registration Number
NCT03922451
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

Phase 3
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2019-03-05
Last Posted Date
2025-02-12
Lead Sponsor
CR-CSSS Champlain-Charles-Le Moyne
Target Recruit Count
158
Registration Number
NCT03862170
Locations
🇨🇦

Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada

P.Acnes Colony Count Following Subdermal Cefazolin

Early Phase 1
Conditions
Microbial Colonization
Surgical Site Infection
Interventions
First Posted Date
2019-02-25
Last Posted Date
2019-02-25
Lead Sponsor
University of British Columbia
Target Recruit Count
20
Registration Number
NCT03853096

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term

Early Phase 1
Completed
Conditions
Obesity
Induction of Labor Affected Fetus / Newborn
Interventions
Drug: Placebo
First Posted Date
2019-01-11
Last Posted Date
2024-04-19
Lead Sponsor
University of Oklahoma
Target Recruit Count
186
Registration Number
NCT03801252
Locations
🇺🇸

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Defining the Optimal Duration of Treatment for "Low-Risk" Peritoneal Dialysis-Related Peritonitis

Phase 4
Withdrawn
Conditions
Peritoneal Dialysis-associated Peritonitis
Interventions
First Posted Date
2018-09-18
Last Posted Date
2019-11-13
Lead Sponsor
Chinese University of Hong Kong
Registration Number
NCT03675854
Locations
🇭🇰

Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong

Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy

Phase 1
Conditions
Renal Replacement Therapy
Pharmacokinetics
Interventions
First Posted Date
2018-09-14
Last Posted Date
2020-10-19
Lead Sponsor
Drexel University
Target Recruit Count
20
Registration Number
NCT03672149
Locations
🇺🇸

St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States

Antibiotic Prophylaxis in Clean Surgery. Impact on Surgical Site Infection

Not Applicable
Completed
Conditions
Surgical Site Infection
Interventions
Drug: Placebos
First Posted Date
2018-07-23
Last Posted Date
2019-09-04
Lead Sponsor
University of Rwanda
Target Recruit Count
138
Registration Number
NCT03595852
Locations
🇷🇼

Kigali University Teaching Hospital (Chuk), Kigali, Rwanda

Bowel Preparation in Elective Pediatric Colorectal Surgery

Not Applicable
Conditions
Hirschsprung Disease - Pull Through
Necrotizing Enterocolitis
Inflammatory Bowel Diseases
Bowel Obstruction
Elective Surgery
Colostomy
Meconium Ileus
Interventions
Other: Nil per os
Other: Clear fluids the day before surgery
First Posted Date
2018-07-20
Last Posted Date
2021-12-09
Lead Sponsor
McMaster University
Target Recruit Count
81
Registration Number
NCT03593252

Does Antibiotic Prophylaxis Reduce Wound Complications After Vulvar Excision of Premalignant Lesions

Phase 2
Completed
Conditions
Premalignant Vulvar Lesion
Benign Vulvar Lesion
Interventions
First Posted Date
2018-07-06
Last Posted Date
2022-11-21
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
50
Registration Number
NCT03578965
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

Phase 4
Terminated
Conditions
Post-Op Wound Infection
Open Fracture
Interventions
Drug: Piperacillin/tazobactam
Drug: Ampicillin/sulbactam
First Posted Date
2018-06-18
Last Posted Date
2020-09-11
Lead Sponsor
Mercy Health Ohio
Target Recruit Count
17
Registration Number
NCT03560232
Locations
🇺🇸

St. Joseph Warren Hospital, Warren, Ohio, United States

🇺🇸

St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy